Nephrotoxicity currently plagues the therapeutic use of cisplatin. Its major side effects are predominantly associated with renal tubular cell apoptosis. In this study, we examined the potential nephroprotective constituents from C. walteri that can exert effects against cisplatin-induced oxidative stress and apoptosis in renal tubular epithelial (LLC-PK1) cells. Phytochemical investigation of the MeOH extract of the stems and stem barks of C. walteri led to the isolation of the potential nephroprotective constituents
Introduction
Cisplatin (cis-diamminedichloroplatinum(II), CDDP) is very efficacious as a rst-line therapy for malignant tumors in organs such as the testis, head, and ovaries. 1, 2 However, cisplatin treatment results in not only the damage of tumor cells but also the tissue cells. 3 Cisplatin is especially toxic to the proximal tubule cells of the kidney, resulting in kidney dysfunction. 4 Recent cisplatin-targeted nephroprotection studies have focused on the search for natural products with enormous structural and chemical diversity, 5, 6 because reducing cisplatininduced nephrotoxicity will not only maximize its clinical outcomes, but can be benecial to patients receiving cisplatin chemotherapy.
Cornus walteri Wanger, well-known as Walter's dogwood, is a deciduous shrub belonging to the family Cornaceae. C. walteri is distributed in Asian countries, specically China and Korea as an economic crop. This tree is best known as a raw material for high-grade furniture and agricultural tools. It is also cultivated for its showy, edible berries. Traditionally, its fruits and leaves are used to treat dermatologic inammation caused by lacquer poison, as indicated in the Chinese Materia Medica. 7 Its leaves are used as an antidiarrheal in Korean folk medicine. 8 According to previous phytochemical studies, C. walteri possesses a variety of bioactive secondary metabolites such as lignans, isoquercitrin, and triterpenoids. [9] [10] [11] The extract of C. walteri has also been shown to inhibit NO production in lipopolysaccharide (LPS)-activated RAW 264.7 macrophages. 12 The leaves of this plant also have protective effects against UVBinduced photoaging in human reconstituted skin. 7 However, the stem of C. walteri has not been under-developed and utilized.
In our continued quest to discover biologically novel natural products from a variety of Korean natural resources, [13] [14] [15] [16] [17] our group has explored the potential bioactive constituents of C. walteri. 11, 18, 19 Our previous studies reported that the MeOH extract of the stems and stem barks of C. walteri are signicantly cytotoxic. 11 The cytotoxic effects of triterpenoids and d-valerolactones have also been elucidated in the our studies. 11, 18, 19 These ndings were our motivation to further investigate potential bioactive constituents in the MeOH extract of C. walteri. Hence, in this study, we performed advanced phytochemical analyses to examine the potential nephroprotective constituents of the MeOH extract of C. walteri, leading to the successful isolation of 15 compounds (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) . We therefore report the isolation and structural elucidation of these compounds and the evaluation of their protective effects against cisplatin-induced nephrotoxicity in renal tubular epithelial (LLC-PK1) cells.
Results and discussion
C. walteri stems and stem barks collected from Jeju Island, Korea were extracted with 80% aqueous MeOH under reux, and then evaporated under a vacuum to obtain a MeOH crude extract, which was subsequently solvent-fractionated with hexane, CHCl 3 , and n-BuOH, yielding soluble fractions of each solvent. Signicant spots were detected in the hexane-soluble fraction aer TLC analysis, and the hexane-soluble fraction was subjected to repeated column chromatography and HPLC purication, which resulted in the isolation of 15 compounds, including seven triterpenoids (1-7), ve steroids (8) (9) (10) (11) (12) , two diterpene analogs (13 and 14) , and one phenolic compound (15) . Based on a comparison of their spectroscopic (including 1 H and 13 C NMR) and physical data with previously reported values and LC/MS analyses, the chemical structures of all the isolates were determined and identied as: leucophyllone (1), 11 3-O-acetylbetulin (2), 20 betulinic acid methyl ester (3), 21 lupenone (4), 22 methyl 3-O-acetylbetulinate (5), 23 lupeol (6), 24 betulinic acid (7) , 25 6b-hydroxysitostenone (8), 26 sitostenone (9), 27 5astigmast-3,6-dione (10), 28 3b-sitostanol (11), 29 6a-hydroxy-bsitostenone (12), 30 norphytan (13), 31 phytone (14), 32 and benzyl salicylate (15) 33 (Fig. 1A) .
Renal tubular cell death induced by oxidative stress and apoptosis is a common feature of cisplatin-induced nephrotoxicity. 4, 34 The effects of cisplatin and/or compounds isolated from C. walteri on cell viability were determined using the Ez-Cytox (tetrazolium salt, WST-1) cell viability assay. Among the isolated compounds (1-15) tested, 6b-hydroxysitostenone (HS) (8) and benzyl salicylate (BS) (15) displayed signicant protective effects against cisplatin-induced renal tubular epithelial cell damage (Fig. S1 †). As shown in Fig. 1 , an approximately 40% signicant decrease in cell viability was observed in the 25 mM cisplatin-treated group compared with the control group (100% cell viability). Meanwhile, co-treatment with HS (25, 50, and 100 mM) and BS (10, 25, 50, and 100 mM) signicantly increased cell viability to 78.5 AE 1.6% and 91.4 AE 1.2%, respectively, compared with the respective cisplatintreated groups (Fig. 1 ). Interestingly, 100 mM BS was as potent as 100 mM quercetin, a frequently studied compound with excellent antioxidant properties in in vivo and in vitro models of cisplatin-induced nephrotoxicity ( Fig. 1 ). [35] [36] [37] [38] To determine the effects of BS (50 and 100 mM) on cisplatininduced LLC-PK1 cell morphological changes and nuclear condensation, Hoechst 33342 staining was used. As shown in Fig. 2A , no changes were observed in the control group, whereas the cisplatin-treated group showed changes in cell shape and structure such as shrinkage as well as round and blebbing morphology. Furthermore, uorescence microscopy images of the cisplatin-treated group had a higher bright blue-uorescence, compared with the control group ( Fig. 2B) . Conversely, the BS-treated (50 and 100 mM) LLC-PK1 cells revealed attenuation of the cisplatin-induced changes in their cell shape, structure, and nuclear condensation, which were changes leading to apoptotic cell death ( Fig. 2 ). 39 ROS generation is one of the potential mechanisms for cisplatin-induced renal tubular epithelial cell damage and a hallmark of the induction of apoptosis. 40, 41 The effects of cisplatin and/or BS on ROS generation were determined using H 2 DCFDA (2 0 ,7 0 -dichlorodihydrouorescein diacetate). As indicated in Fig. 3A , uorescence microscopy images of the cisplatin-treated group had a higher bright green-uorescence compared with the control group because nonuorescent H 2 DCFDA is converted to the uorescent 2 0 ,7 0 -dichloro-uorescein (DCF) upon oxidation by ROS, whereas the BStreated (50 and 100 mM) LLC-PK1 cells revealed attenuation of cisplatin-induced elevated intracellular ROS. As shown in Fig. 3B , quantitative analyses showed that the cisplatin-induced elevated intracellular ROS levels (7.37-fold increase) were signicantly reduced by BS (50 and 100 mM) (4.20-and 2.68-fold increases, respectively). Cisplatin intensies the generation of kidney oxidative stress, associated with the decrease of proximal tubule cell viability through mitochondria and DNA dysfunction. 5 Therefore, BS is a promising antioxidant agent for cisplatin-induced oxidative stress. The nding is in accordance with the study reported previously where quercetin showed the nephroprotective effect in cisplatin-treated rats because of its radical scavenging activity in the kidney tubular cells of rats. 35 The protective effects of BS (50 and 100 mM) were investigated on cisplatin-induced cell death process in LLC-PK1 cells using staining with annexin V conjugated with Alexa Fluor 488 that can detect phosphatidylserine on the cell surface of apoptotic cells and propidium iodide (PI) that can detect necrotic cells by staining DNA and RNA inside of necrotic cells. Increased apoptosis (bright green color) was observed in the cisplatin-treated group compared with the control group (Fig. 4A) . Conversely, the BS-treated (50 and 100 mM) LLC-PK1 cells attenuated the cisplatin-induced apoptosis. These results indicate that BS (50 and 100 mM) protects against cisplatininduced LLC-PK1 cell death by inhibiting apoptosis. Quantitative analyses showed a signicant 61.45 AE 4.78% increase in the percentage of apoptotic cells stained with annexin V in the 25 mM cisplatin-treated group compared with the control group (1.25 AE 0.52%; Fig. 4B ). Conversely, BS treatment (50 and 100 mM) signicantly decreased the percentage of apoptotic cells to 30.91 AE 4.09% and 14.20 AE 2.40%, respectively, compared with the cisplatin-treated group. In addition, quantitative analyses showed a signicant decrease in the percentage of live cells in the 25 mM cisplatin-treated group (37.21 AE 0.05%) compared with the control group (97.75 AE 0.01%; Fig. 4B ). Conversely, 50 and 100 mM BS treatments signicantly increased the percentage of live cells to 67.75 AE 0.05% and 84.13 AE 0.03%, respectively, compared with the cisplatin-treated group. Percentage of necrotic cells stained with PI did not show signicant changes. These results indicate that BS inhibited cisplatin-induced apoptosis. The nding is in agreement with earlier studies, where low concentration of cisplatin induces apoptotic cell death, whereas higher concentration of cisplatin induces necrotic cell death. 42 To investigate the protective effects of BS (50 and 100 mM) on the underlying apoptotic pathway, we focused on evaluating the regulation of the mitogen-activated protein kinase (MAPK) pathways such as extracellular signal-regulated kinases (ERK), c-Jun N-terminal kinases (JNK), and p38. ERK, JNK, and p38 are important for the stress response and cell death, thus, are essential factors in cisplatin-induced apoptosis in renal tubular epithelial cells. 34, 43 A previous study revealed that the anti- apoptotic effect of quercetin in the cisplatin-treated rats is caused by suppression of the JNK. 38 BS treatment (50 and 100 mM) attenuated protein expression levels of MAPKs (p-JNK, p-ERK, and p-p38), compared with the levels in the cisplatintreated group (Fig. 5A) . Overall, the observed downregulation of JNK, p-ERK, and p-p38 by BS treatment (50 and 100 mM) may be indicative of its protective, anti-apoptotic role in cisplatininduced LLC-PK1 cell damage.
We also investigated the effects of BS (50 and 100 mM) on Bax/Bcl-2 and cleaved caspase-8, -9, and -3 activation. In the apoptosis pathway, the anti-apoptotic protein Bcl-2 and proapoptotic protein Bax are apoptotic regulatory proteins. Downregulation of Bcl-2 inhibits renal tubular epithelial cell death. When apoptosis is initiated, Bax is translocated to the mitochondrial membrane, leading to subsequent cisplatin-induced activation of caspases in renal tubular epithelial cells. 42, 44 Compared with the cisplatin-treated group, BS treatment (50 and 100 mM) signicantly inhibited the expression of Bax and increased the expression of Bcl-2, which resulted in a decreased Bax/Bcl-2 ratio (Fig. 6A ). In addition, activated initiator caspases-8, and -9, and executioner caspase-3 were observed in cisplatin-induced renal tubular epithelial cell death. 42, 45 BS treatment (50 and 100 mM) signicantly attenuated the protein expression of cleaved caspase-9 and -3, compared with the levels in the cisplatin-treated group. However, activation of caspase-8 were not regulated signicantly by treatment of BS. Overall, our results indicate that BS treatment (50 and 100 mM) modulated the Bax/Bcl-2 ratio by down-regulating the activation of caspase-9 and -3. Therefore, the protective effect of BS against cisplatininduced renal tubular epithelial cell damage was mediated through intrinsic apoptotic pathway.
Conclusion
In this study, we examined the potential of constituents of C. walteri against cisplatin-induced nephrotoxicity in LLC-PK1 cells, which led to the successful identication of the renoprotective compound benzyl salicylate (BS). BS inhibited cisplatininduced oxidative stress and apoptosis in renal tubular epithelial cells. In addition, the anti-apoptotic mechanism employed by BS was attributed to the regulation of the protein expression of Bax, Bcl-2, cleaved caspase-9 and -3. These results suggest BS as a novel promising renoprotective agent against cisplatin-induced nephrotoxicity. Furthermore, further in vivo and in vitro studies are required to validate the mechanisms by which BS protects against cisplatin-induced renal tubular epithelial cell death. Our present study further supported the potential of BS as a promising therapeutic candidate that benets to nephroprotective effects.
Experimental section

General experimental procedures
Optical rotations were measured using a Jasco P-1020 polarimeter (Jasco, Easton, MD, USA). IR spectra were recorded with a Bruker IFS-66/S FT-IR spectrometer (Bruker, Karlsruhe, Germany). UV spectra were obtained using an Agilent 8453 UVvisible spectrophotometer (Agilent Technologies, Santa Clara, CA, USA Extraction and isolation C. walteri stems and stem barks (2.5 kg) were dried, chopped, and crude extracts were prepared using 80% aqueous MeOH (2 Â 6 h) under reux, and then ltered. The ltrate was evaporated under a vacuum to obtain a MeOH extract (220 g), which was suspended in distilled H 2 O (7.2 L) and then successively partitioned with hexane, CHCl 3 , and n-BuOH, yielding 9.5, 25.0, and 43.0 g of residue, respectively. The hexane-soluble fraction (9.5 g) was chromatographed on a silica gel (230-400 mesh, 300 g) column eluted with hexane-EtOAc (3 : 1 to 1 : 1, gradient system), to yield fractions H1-H5. Fraction H1 (4.0 g) was separated using an RP-C 18 silica gel column using 100% MeOH, to acquire ve fractions (H11-H15). Fraction H12 (800 mg) was subjected to a Sephadex LH-20 column using a solvent system of dichloromethane-MeOH (1 : 1), to give subfractions H121-H122. To obtain compound 15 (12 mg), fraction H122 (50 mg) was subjected to a silica gel Waters Sep-Pak Vac 6 cc with hexane-EtOAc (30 : 1). Fraction H13 (800 mg) was further separated using silica gel column chromatography eluting a gradient solvent system of hexane-EtOAc (7 : 1 to 1 : 1, v/v), to provide 6 subfractions (H131-H136). Compound 12 (6 mg) was puried from subfraction H131 (100 mg) using semipreparative normal-phase HPLC (Apollo Silica column, 250 Â 10.0 mm, 5 mm, ow rate: 2 mL min À1 ) and eluted with an isocratic solvent system of hexane-EtOAc (18 : 1, v/v). Five subfractions (H141-H145) were acquired from fraction H14 (300 mg) using silica gel column chromatography with a gradient solvent system of hexane-EtOAc (16 : 1 to 1 : 1, v/v).
To obtain compound 2 (40 mg), subfraction H142 (50 mg) was isolated using semi-preparative normal-phase HPLC (Apollo Silica column, 250 Â 10.0 mm, 5 mm, ow rate: 2 mL min À1 ) with an isocratic solvent system of hexane-EtOAc (28 : 1, v/v). Compound 13 (30 mg) was obtained from subfraction H144 (50 mg) using semi-preparative normal-phase HPLC (Apollo Silica column, 250 Â 10.0 mm, 5 mm, ow rate: 2 mL min À1 ) eluted with an isocratic solvent system of hexane-EtOAc (12 : 1, v/v). To obtain compound 3 (7 mg), fraction H15 (100 mg) was separated using a C18 Sep-Pak column eluting an isocratic solvent system of hexane-EtOAc (10 : 1, v/v) and further isolated using semi-preparative normal-phase HPLC (Apollo Silica column, 250 Â 10.0 mm, 5 mm, ow rate: 2 mL min À1 ) with an isocratic solvent system of hexane-EtOAc (20 : 1, v/v). Fraction H2 (2.5 g) was loaded onto an RP-C 18 silica gel column and separated by eluting with 100% MeOH to obtain eight fractions (H21-H28). Compound 8 (60 mg) was isolated from fraction H27 (150 mg) using semi-preparative normal-phase HPLC (Apollo Silica column, 250 Â 10.0 mm, 5 mm, ow rate: 2 mL min À1 ) with an isocratic solvent system of hexane-EtOAc (8 : 1, v/v). Fraction H28 (100 mg) was isolated using semipreparative normal-phase HPLC (Apollo Silica column, 250 Â 10.0 mm, 5 mm, ow rate: 2 mL min À1 ) with an isocratic solvent system of hexane-EtOAc (8 : 1, v/v) to obtain compound 7 (25 mg). Fraction H3 (1.7 g) was loaded onto an RP-C 18 silica gel column and fractionated by eluting with 100% MeOH to obtain six fractions (H31-H36). Fraction H32 (200 mg) was separated by reverse-phase Lobar column with an isocratic solvent system of hexane-EtOAc (4 : 1, v/v) to obtain four subfractions (H321-H324). Compound 5 (4 mg) was obtained from subfraction H321 (150 mg) using semi-preparative reverse-phase HPLC (Econosil C18 column, 250 Â 10.0 mm, 5 mm, ow rate: 2 mL min À1 ) eluting with an isocratic solvent system of 95% MeOH. Fraction H33 (400 mg) was fractionated using a reversephase Lobar column with an isocratic solvent system of hexane-EtOAc (4 : 1, v/v) to obtain ve subfractions (H331-H335). Fraction H331 (50 mg) was puried using semi-preparative reverse-phase HPLC (Econosil C18 column, 250 Â 10.0 mm, 5 mm, ow rate: 2 mL min À1 ) with an isocratic solvent system of 100% MeOH to give compound 1 (7 mg). Compound 14 (30 mg) was obtained from fraction H34 (120 mg) using semipreparative normal-phase HPLC (Apollo Silica column, 250 Â 10.0 mm, 5 mm, ow rate: 2 mL min À1 ) with an isocratic solvent system of hexane-EtOAc (3 : 1, v/v). Compounds 9 (5 mg) and 10 (8 mg) were puried from fraction H36 (120 mg) using semipreparative normal-phase HPLC (Apollo Silica column, 250 Â 10.0 mm, 5 mm, ow rate: 2 mL min À1 ) with an isocratic solvent system of hexane-EtOAc (4 : 1, v/v). Fraction H4 (1.3 g) was loaded onto an RP-C 18 silica gel column and fractionated by eluting with 100% MeOH to give six fractions (H41-H46).
Fraction H44 (120 mg) was isolated using semi-preparative normal-phase HPLC (Apollo Silica column, 250 Â 10.0 mm, 5 mm, ow rate: 2 mL min À1 ) with an isocratic solvent system of hexane-EtOAc (2 : 1, v/v) to obtain compounds 4 (5 mg) and 6 (25 mg). Fraction H5 (500 mg) was fractionated using an RP-C18 silica gel column with an isocratic solvent system of 85% MeOH to obtain ve fractions (H51-H55). Fraction H51 (150 mg) was passed over the Sephadex-LH20 column with CHCl 3 -MeOH (1 : 1, v/v) and further puried using semi-preparative reversephase HPLC (Econosil C18 column, 250 Â 10.0 mm, 5 mm, ow rate: 2 mL min À1 ) eluting with an isocratic solvent system of 100% MeOH to obtain compound 11 (6 mg).
Cell culture
The pig kidney epithelial cell line (LLC-PK1) was used to investigate the nephroprotective effect against cisplatininduced renal cell damage. LLC-PK1 cells were purchased (American Type Culture Collection, Rockville, MD, USA) and grown to 80% conuence with DMEM containing 10% FBS, 1% penicillin/streptomycin, and 4 mM L-glutamine at 37 C with 5% carbon dioxide and 95% relative humidity.
Renoprotective effect against cisplatin-induced kidney cell damage LLC-PK1 cells were plated onto 96-well culture plates (1 Â 10 4 cells per well). Aer 24 h, they were exposed to various concentrations of the isolated compounds in the presence of 25 mM cisplatin for 24 h. The relative percent cell viability was assessed with the Ez-Cytox reagent kit (Daeil Lab Service, Seoul, Korea), following the manufacturer's instructions. The optical densities (OD) were measured at 450 nm using a microplate reader (PowerWave XS; Bio-Tek Instruments, Winooski, VT, USA).
Determination of intracellular ROS
The cells were plated onto 6-well culture plates (1 Â 10 4 cells per well). Aer 24 h, they were exposed to 50 or 100 mM benzyl salicylate (BS) in the presence of 25 mM cisplatin for 24 h. The LLC-PK1 cells were then stained with 2 0 ,7 0 -dichlorouorescin diacetate (H 2 DCFDA; Sigma Aldrich, St. Louis, MO, USA) for 30 min at 37 C and then washed with PBS. The cells were visualized under the IX50 uorescent microscope (Olympus, Tokyo, Japan) equipped with a CCD camera, and uorescence intensities of DCF at 495 nm excitation and 517 nm emission were measured using a uorescence microplate reader (SPARK 10M; Tecan, Männedorf, Switzerland).
Image-based cytometric assay
To detect the apoptotic cell population, LLC-PK1 cells were plated onto 6-well culture plates (4 Â 10 5 cells per well). Aer 24 h, LLC-PK1 cells were treated with 50 or 100 mM BS in the presence of 25 mM cisplatin. The LLC-PK1 cells were then incubated with Annexin V-Alexa Fluor 488 and PI, following the manufacturer's instructions. The relative percentage of apoptotic, live, and necrotic cells was assessed with the Tali image-based cytometer (Invitrogen, Carlsbad, CA, USA).
Western blotting
The cells were plated into 6-well culture plates (4 Â 10 5 cells per well). Aer 24 h, they were treated with 50 or 100 mM BS in the presence of 25 mM cisplatin. Following the manufacturer's instructions, the LLC-PK1 cells were then lysed with RIPA buffer (Cell Signaling Technology, MA, USA) supplemented with 1 mM phenylmethylsulfonyl uoride for 20 min at 4 C to obtain the cell lysates.
The protein concentrations of cell lysates were quantied using the bicinchoninic acid (BCA) protein assay kit (Thermo Fisher Scientic, Waltham, MA, USA). Equal amounts of
